Draft a Clinical Trial Amendment Impact Summary from a Protocol Change Description

The task

Clinical trial managers, medical monitors, and study startup leads at sponsors and CROs (contract research organizations) draft an Amendment Impact Summary every time a protocol changes — new inclusion criteria, an added assessment, a schedule tweak. It has to spell out what changes, who's affected (sites, IRBs, EHR builds, vendors), and what the operational and regulatory ripple is. It gets attached to change control tickets and circulates to ops, regulatory, data management, and finance before the amendment goes out.

Before AI

Today someone reads the redlined protocol, opens a Word template, and manually maps each change to affected sections: eligibility, schedule of assessments, informed consent, EHR/EDC (electronic data capture) build, IRB/EC filings, site training, vendor contracts. It's 2-4 hours of careful work, and version one usually misses something — like the CRF field that needs a new value set, or the lab kit that now has an extra tube.

The stakes are real. These changes cost anywhere from $141,000 to $535,000 each—not including indirect expenses, and per Tufts CSDD analysis of protocol amendments, the operational complexity is often underestimated. A tighter impact summary upstream means fewer surprises downstream.

The workflow

1. Extract and classify the protocol change

Paste the change description into the prompt below. This step normalizes free-text change requests into a structured record before any downstream reasoning.

You are a senior clinical trial manager helping draft an Amendment Impact Summary. You will be given a free-text protocol change description from a sponsor or medical monitor.

Do NOT include any real patient identifiers in your output. If the input contains anything that looks like PHI (patient names, MRNs, dates of birth, specific site-patient combinations), replace it with [REDACTED] and flag it at the top of your response.

Return a structured record with these fields, in markdown:

- **Amendment type**: Substantial / Non-substantial (per ICH E6(R3)). One-line justification.
- **Change category**: one or more of {Eligibility, Schedule of Assessments, Dosing, Safety Monitoring, Endpoints, Statistical, Informed Consent, Logistics/Vendor, Administrative}.
- **Trigger**: why this change is being made (safety signal, feasibility, regulatory feedback, sponsor decision, etc.). If not stated, write "Not stated — confirm with medical monitor."
- **Sections of the protocol likely affected**: bullet list, using standard protocol section names (e.g., 5.1 Inclusion Criteria, 6.2 Schedule of Assessments).
- **Effective scope**: All sites / Specific sites / Specific cohorts. Note if unclear.

Keep it factual. Do not invent details not present in the input. Where the input is ambiguous, mark the field with "AMBIGUOUS —" and state what's missing.

Here is the change description:

Protocol NEURA-204 (Phase 2b, early Alzheimer's, oral BIA-556 vs placebo).

Medical monitor requests the following change effective at next amendment:

1. Add eGFR ≥ 45 mL/min/1.73m² as an inclusion criterion (currently ≥ 60). Rationale: enrollment is 22% behind plan across all 34 sites; feasibility analysis suggests ~15% of screen failures at Sites 003, 007, 011, 019 are due to the eGFR cutoff. No safety signal to date.

2. Add a mid-cycle safety labs visit at Week 6 (currently only Weeks 4 and 8). Rationale: DSMB recommendation from 15-Aug review after two Grade 2 ALT elevations (both resolved, both on active arm). Adds one blood draw (CBC, CMP, lipase) and one in-person visit; no new assessments.

3. Clarify that the MoCA can be administered in the participant's preferred language from the approved translation list; previously read "in English." Administrative clarification only.

Sponsor wants the amendment filed with FDA and central IRB within 30 days. Approximately 180 participants currently enrolled; 240 target.

2. Generate the operational and regulatory impact map

This is the core deliverable. It takes the structured record from Step 1 and expands it into the sections stakeholders actually need.

Now produce the full Amendment Impact Summary using the structured record above. Use this exact section structure:

## 1. Summary of Changes
One numbered list, one line each. Plain language a site coordinator would understand.

## 2. Regulatory Impact
- Filings required (FDA IND amendment, EMA substantial modification, central IRB, local IRBs/ECs). For each, note likely review path (expedited vs full board) and typical timeline.
- Informed Consent Form: does it need re-consent of enrolled participants? Yes/No/Partial, and why.
- Investigator Brochure / IB update needed? Yes/No.

## 3. Operational Impact
For each affected function, one row in a markdown table with columns: Function | Change required | Owner | Est. effort (S/M/L).
Include at minimum: Clinical Operations, Data Management (EDC/CRF build), EHR/EMR site build (where applicable), Central & Local Labs, IMP/Drug Supply, Site Training, Monitoring Plan, Safety/Pharmacovigilance, Biostatistics/SAP, Vendors (imaging, ePRO, central rater, etc.).
Only include rows with actual impact. Omit "No change" rows.

## 4. Participant Impact
- Currently enrolled participants: what changes for them?
- Screen-in-progress participants: any protocol-driven pauses?
- Any additional burden (extra visits, extra blood volume, new questionnaires)?

## 5. HIPAA / Privacy Considerations
Flag anything that changes the data collected, who accesses it, or how it's transmitted (e.g., new vendor, new data element, new EHR extract). If nothing changes, write "No new PHI elements introduced; existing data handling per protocol Section [X] applies."

## 6. Risks & Open Questions
Bullet list. Include items that need a human decision before the amendment is finalized.

Rules:
- If the input didn't give you enough to answer a section, write "Requires input from [role]" — do NOT invent details.
- Do not estimate dollar costs; sponsors calculate those internally.
- Do not name specific IRBs, vendors, or FDA reviewers.

3. Produce the stakeholder-facing one-pager

Different audiences need different framings. This step compresses the full summary into an executive-friendly note plus a site-facing note.

Now produce two short companion documents based on the Amendment Impact Summary above.

### A. Executive one-pager (for sponsor leadership / CRO PM)
Max 200 words. Cover: what's changing, why, regulatory path, estimated impact on enrollment timeline and site burden, top 3 risks. No table.

### B. Site notification draft (for CRAs to share with PIs and coordinators)
Max 250 words, plain English, second person ("your site"). Cover: what changes at the site, when it takes effect (pending IRB), whether re-consent is needed, any new workflow steps (visits, labs, EDC fields), and who to contact with questions. End with "This is a draft pending IRB approval — do not implement until formal notification."

Do not add greetings, signatures, or dates. Do not invent contact names.

Gotchas

• The model will confidently guess regulatory timelines. Treat any "expedited review, 5 business days" claim as a placeholder. Real timelines depend on your specific IRB, region, and whether the change is safety-driven. Have regulatory affairs confirm.
• EHR/EDC impact is the section most likely to be underspecified. If your CRF build has custom edit checks or lab reference ranges hard-coded, the model won't know. Loop in your data manager before finalizing.
• "No new PHI" is easy to get wrong. Adding a new lab, a new questionnaire, or a new vendor almost always changes the data flow. Read Section 5 with a privacy officer, not just a coordinator.
• Re-consent decisions are legal calls. The model can suggest whether re-consent is likely needed based on the nature of the change, but the final call belongs to your IRB and regulatory lead — especially for changes that alter risk/benefit.
• Don't paste real participant data. The prompt has a redaction instruction, but the safer habit is to strip identifiers before pasting. The change description should reference cohorts and site numbers, not participants.
• Multi-region trials break the single-summary model. If you're running in US + EU + APAC, the regulatory section needs a per-region pass. Run Step 2 once per region or add region-specific language to the prompt.

Time saved

Manual drafting of an Amendment Impact Summary from a change description typically runs 2-4 hours for a mid-complexity Phase 2/3 amendment, plus another hour for the executive and site-facing versions. This workflow gets you to a reviewable draft in 15-20 minutes. Call it 2-3 hours saved per amendment, conservatively.

Volume matters: Tufts CSDD reports that 76 percent of phase 1–4 protocols now have at least one amendment (up from 57 percent in 2015), with a mean of 3.3 amendments per protocol. For a sponsor or CRO running dozens of active studies, that's meaningful capacity back to the clinical operations team — and, per the MedCity News piece on agentic AI in trial operations, a step toward shorter amendment cycles overall.

What we got when we ran it

We executed every prompt above, in order, against the sample input (model: claude-sonnet-4-6). Outputs below are real and unedited apart from length truncation.

Step 1 output

# Amendment Impact Summary — Protocol NEURA-204 > PHI/Confidential Data Flag: No patient-level PHI detected in the input. Site numbers (003, 007, 011, 019) are site identifiers only and do not constitute PHI; they are retained as operationally relevant. No action required. --- ## Change 1 — eGFR Inclusion Criterion Relaxation | Field | Detail | |---|---| | Amendment type | Substantial — Modifies an eligibility criterion in a way that changes the enrolled population's renal function profile, potentially affecting drug exposure and safety interpretation. Per ICH E6(R3), changes to inclusion/exclusion criteria that alter the benefit-risk profile for participants qualify as substantial. | | Change category | Eligibility | | Trigger | Feasibility / enrollment lag — enrollment is 22% behind plan; feasibility analysis identified the eGFR ≥ 60 cutoff as a material driver of screen failure at multiple sites. No safety signal reported as triggering this specific change. | | Protocol sections likely affected | - 5.1 Inclusion Criteria (primary change: eGFR threshold from ≥ 60 to ≥ 45 mL/min/1.73m²) <br> - 5.3 Screen Failure Criteria / Screening Procedures (if eGFR is referenced as a screening lab) <br> - 8.x Safety Monitoring / Laboratory Assessments (may need annotation that participants with eGFR 45–59 require additional renal monitoring — AMBIGUOUS — confirm with medical monitor whether enhanced monitoring is warranted for this subgroup) <br> - Synopsis / Study Design Summary (eligibility summary table) <br> - Informed Consent Form (ICF) (eligibility language update required) | | Effective scope | **All 34

…output truncated at 250 words.

Step 2 output

# Amendment Impact Summary ## Protocol NEURA-204 | Phase 2b | Oral BIA-556 vs Placebo | Early Alzheimer's Disease ### Draft for Medical Monitor Review — Version 1.0 | Date: [INSERT DATE] > PHI Flag: No patient-level PHI detected in the source input. Site identifiers (003, 007, 011, 019) are retained as operationally relevant. No redaction required. --- ## 1. Summary of Changes 1. Eligibility — eGFR threshold lowered: The minimum kidney function required to enroll has been reduced from eGFR ≥ 60 to eGFR ≥ 45 mL/min/1.73m². More participants who were previously screened out due to mildly reduced kidney function will now qualify. 2. New safety visit at Week 6: All participants must now come in for an additional in-person visit at Week 6. A single blood draw will be taken for three lab tests: complete blood count (CBC), comprehensive metabolic panel (CMP), and lipase. This visit was not previously in the schedule. 3. MoCA language clarification: The cognitive test (MoCA) may now be administered in the participant's preferred language, as long as that language is on the sponsor's approved translation list. The previous protocol text incorrectly limited administration to English only. --- ## 2. Regulatory Impact ### Filings Required | Filing | Classification | Likely Review Path | Typical Timeline | |---|---|---|---| | FDA IND Amendment | Changes 1 and 2 constitute a substantial protocol amendment under 21 CFR 312.30(b). Change 3 may be filed as an administrative amendment but should be bundled into a single submission for

…output truncated at 250 words.

Step 3 output

# Companion Documents — Protocol NEURA-204 Amendment --- ## A. Executive One-Pager Protocol NEURA-204 | Phase 2b | BIA-556 vs Placebo | Early Alzheimer's Disease Three protocol changes are being filed as a single bundled amendment. First, the eGFR inclusion threshold is being lowered from ≥ 60 to ≥ 45 mL/min/1.73m² to address an enrollment deficit of approximately 22% across all 34 sites; no safety signal drove this change. Second, a mandatory Week 6 safety lab visit is being added following a DSMB recommendation triggered by two resolved Grade 2 ALT elevations on the active arm. Third, MoCA administration language is being clarified to permit approved translations; this is administrative only. The amendment requires an FDA IND submission and central IRB review within 30 days. Full board IRB review is likely given the safety-driven visit addition, which may constrain the filing timeline. All currently enrolled participants (~180 of 240 target) must be re-consented before the Week 6 visit change applies to them. The eGFR change is expected to meaningfully reduce screen failure rates and accelerate enrollment toward target. The Week 6 visit adds site and participant burden across the remaining study period. Top three risks: 1. Full board IRB review may not complete within the 30-day sponsor target. 2. PK/safety data supporting enrollment of participants with eGFR 45–59 must be confirmed before implementation. 3. Whether participants already past Week 6 require a retroactive visit remains unresolved and needs Medical Monitor decision. --- ## B. Site Notification Draft **Protocol NEURA-204 —

…output truncated at 250 words.

---

This content is for informational purposes only and is not medical advice. AI tools used with patient data must meet your organization's HIPAA and privacy requirements.